A Study to Assess the Drug-drug Interaction of BMS-963272 and Rosuvastatin

NCT ID: NCT04124003

Last Updated: 2020-03-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-08

Study Completion Date

2020-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 1 study that assesses the effect of BMS-963272 on exposure of rosuvastatin in healthy participants

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

rosuvastatin + BMS-963272

Group Type EXPERIMENTAL

rosuvastatin

Intervention Type DRUG

Specified dose on specified days

BMS-963272

Intervention Type DRUG

Specified dose on specified days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rosuvastatin

Specified dose on specified days

Intervention Type DRUG

BMS-963272

Specified dose on specified days

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy participants, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
* Women must not be of childbearing potential (WNOCBP)
* Women and men must agree to follow instructions for methods of contraception

Exclusion Criteria

* Any significant acute or chronic medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study.
* Any major surgery within 4 weeks of study drug administration
* Any blood transfusion or donation of blood to a blood bank or in a clinical study within 4 weeks of study drug administration
* Previous treatment with BMS-963272
* Participants who smoke, as well as, those who have stopped smoking less than 6 months prior to day 1
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bristol-Myers Squibb

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

PRA Health Sciences - Salt Lake

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MB006-018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study on Pharmacokinetics
NCT02234882 COMPLETED PHASE1